DURECT (DRRX)
(Delayed Data from NSDQ)
$1.34 USD
-0.03 (-2.19%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.29 -0.05 (-3.73%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
DURECT Corporation [DRRX]
Reports for Purchase
Showing records 81 - 100 ( 144 total )
Company: DURECT Corporation
Industry: Medical - Drugs
PERSERIS Approval Is Nice; But Our Thesis Remains Focused on DUR-928; Adjust PT to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
All About DUR-928:Two Shots on Goal in 2018; Upgrading to Buy, $3.50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
3Q Recap: Focused on Multiple POC Trials of DUR-928 in 2018; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
Posimir Fails to PERSIST; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
2Q Recap: Pivotal Posimir Data and Initiating a Phase 2 DUR-928 Study in PSC, Both in 4Q; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
Early Completion of Enrollment for PERSIST Is an Incremental Positive for Posimir; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
1Q Recap: Novartis Partnership for Posimir; Clear Development Path for DUR-928; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
Company: DURECT Corporation
Industry: Medical - Drugs
NASH SPLASH: Highlights From Our Inaugural NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Agenda for Our First Annual NASH Investor Conference on April 3 in NY
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
4Q16 Recap: First Clinical Data of DUR-928 in NASH Expected Next Month; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
We are assume coverage with a Buy rating and $3.00 price target.
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E